Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for VistaGen Therapeutics, Inc. (VTGN : NSDQ)
 
 • Company Description   
VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Number of Employees: 21

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.19 Daily Weekly Monthly
20 Day Moving Average: 884,391 shares
Shares Outstanding: 206.53 (millions)
Market Capitalization: $245.77 (millions)
Beta: 0.93
52 Week High: $3.55
52 Week Low: $1.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.19% -13.65%
12 Week -14.39% -7.11%
Year To Date -38.97% -27.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
343 ALLERTON AVENUE
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-577-3600
fax: 888-482-2602
mflather@vistagen.com http://www.vistagen.com
 
 • General Corporate Information   
Officers
Shawn K. Singh - Chief Executive Officer; and Director
Jon S. Saxe - Chairman
H. Ralph Snodgrass - President; Chief Scientific Officer and Director
Jerrold D. Dotson - Vice President and Chief Financial Officer
Ann M. Cunningham - Director

Peer Information
VistaGen Therapeutics, Inc. (CORR.)
VistaGen Therapeutics, Inc. (RSPI)
VistaGen Therapeutics, Inc. (CGXP)
VistaGen Therapeutics, Inc. (BGEN)
VistaGen Therapeutics, Inc. (GTBP)
VistaGen Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92840H202
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 07/05/22
Share - Related Items
Shares Outstanding: 206.53
Most Recent Split Date: (:1)
Beta: 0.93
Market Capitalization: $245.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.97
Price/Cash Flow: -
Price / Sales: 162.55
EPS Growth
vs. Year Ago Period: 28.57%
vs. Previous Quarter: 28.57%
Sales Growth
vs. Year Ago Period: 14.01%
vs. Previous Quarter: 0.00%
ROE
03/31/22 - -
12/31/21 - -44.10
09/30/21 - -36.41
ROA
03/31/22 - -
12/31/21 - -36.99
09/30/21 - -30.38
Current Ratio
03/31/22 - -
12/31/21 - 13.51
09/30/21 - 12.19
Quick Ratio
03/31/22 - -
12/31/21 - 13.51
09/30/21 - 12.19
Operating Margin
03/31/22 - -
12/31/21 - -2,465.94
09/30/21 - -2,183.17
Net Margin
03/31/22 - -
12/31/21 - -2,465.94
09/30/21 - -2,183.17
Pre-Tax Margin
03/31/22 - -
12/31/21 - -2,465.68
09/30/21 - -2,182.90
Book Value
03/31/22 - -
12/31/21 - 0.40
09/30/21 - 0.42
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©